Doctors warned to be wary of new drugs
BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7346.1113 (Published 11 May 2002) Cite this as: BMJ 2002;324:1113- Deborah Josefson
- Nebraska
Doctors should be wary of starting their patients on newly approved drugs, because of the high rate of adverse side effects that go undetected until late in the post-marketing surveillance period, a new study says (JAMA 2002;287:2215-20).
More than 10% of new drugs approved by the Food and Drug Administration (FDA) have serious side effects that are not discovered on initial testing and marketing, says the study, led by Dr Karen Lasser and Dr Paul Allen of the Department of Medicine at Cambridge Hospital in Cambridge, Massachusetts.
The investigators analysed 548 drugs approved by the FDA from 1975 to 1999. The list …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.